Elaboration and evaluation of alginate foam scaffolds for soft tissue engineering

[Display omitted] Controlling microarchitecture in polymer scaffolds is a priority in material design for soft tissue applications. This paper reports for the first time the elaboration of alginate foam-based scaffolds for mesenchymal stem cell (MSC) delivery and a comparative study of various surfa...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 524; no. 1-2; pp. 433 - 442
Main Authors Ceccaldi, Caroline, Bushkalova, Raya, Cussac, Daniel, Duployer, Benjamin, Tenailleau, Christophe, Bourin, Philippe, Parini, Angelo, Sallerin, Brigitte, Girod Fullana, Sophie
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 30.05.2017
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] Controlling microarchitecture in polymer scaffolds is a priority in material design for soft tissue applications. This paper reports for the first time the elaboration of alginate foam-based scaffolds for mesenchymal stem cell (MSC) delivery and a comparative study of various surfactants on the final device performance. The use of surfactants permitted to obtain highly interconnected porous scaffolds with tunable pore size on surface and in cross-section. Their mechanical properties in compression appeared to be adapted to soft tissue engineering. Scaffold structures could sustain MSC proliferation over 14 days. Paracrine activity of scaffold-seeded MSCs varied with the scaffold structure and growth factors release was globally improved in comparison with control alginate scaffolds. Our results provide evidence that exploiting different surfactant types for alginate foam preparation could be an original method to obtain biocompatible scaffolds with tunable architecture for soft tissue engineering.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2017.02.060